Facebook Reiterated at Outperform and 4 Stock Analyses Making Rounds

Bill Barrett Corp. (NYSE:BBG): Current Price: $17.65

According to SunTrust, any potential weakness in the company’s shares are likely related to the CEO departure, and this creates a buying opportunity. The analyst has stated that shares are currently trading below break-up value, and upcoming catalysts include formal guidance and proved reserves. The shares have a Buy rating and a $26 price target.

Capture

 

Save time and make money with our LOWEST ADVERTISED PRICE EVER to help you achieve your financial goals in 2013. This is a LIMITED TIME OFFER, so get your Stock Picker Newsletter now!

Heartland Payment Systems, Inc. (NYSE:HPY): Current Price: $30.42

Baird has labeled Heartland Payment as a best idea for 2013, and the firm believes that the company’s acquisition of Ovation Payroll is positive. The firm noted Heartland’s strong revenue growth profile, leverage, and accretive potential. Shares have an Outperform rating and a $40 price target.

Capture

 

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

Facebook, Inc. (NASDAQ:FB): Current Price: $29.09

The company’s price target has been increased by Baird, and the firm also decided to reiterate its positive view due to the company’s consumer leverage potential and targeted marketing opportunities. The firm decided to increase its estimates considering the company’s mobile revenues, improving ad quality, and the emerging ad/exchange network. Shares have an Outperform rating.

Capture

 

Save time and make money with our LOWEST ADVERTISED PRICE EVER to help you achieve your financial goals in 2013. This is a LIMITED TIME OFFER, so get your Stock Picker Newsletter now!

Pinnacle Entertainment Inc. (NYSE:PNK): Current Price: $16.15

The company’s price target has been increased by Brean Capital after the company¬†announced¬†that it intends to acquire Ameristar Casino (NASDAQ:ASCA). The firm views this deal as being immediately accretive and it will add to cash flow. Furthermore, the firm also predicts that revenue growth will be driven by targeted marketing along with the company’s strong pipeline and financial footing. Shares have a Buy rating.

Capture

 

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA): Current Price: $19.15

Brean Capital decided to reduce its price target on ARIAD asa way to reflect revenue adjustments and as a discount to its cash flow rate. The firm continues to be positive on ARIAD due to its commercialization efforts of ponatinib, which includes its expansion into Europe, Japan, and other countries. Ariad shares have a Buy rating.

Capture

Don’t Miss: Is Verizon Contemplating an Acquisition?